English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Potential effects on cardiac repolarization of single doses of moxidectin, a potent long‐acting macrocyclic lactone endectocide, were assessed in a concentration‐ QT  (c‐QT; exposure‐response) study. This double‐blind, placebo‐controlled, parallel‐group study in healthy male volunteers ( n  = 60) randomized subjects to a single oral dose of moxidectin (4 mg, 8 mg, 16 mg, 24 mg, or 36 mg) or matching placebo. Serial plasma samples for pharmacokinetic (PK) analysis and concurrent triplicate electrocardiogram measurements were taken at baseline and 14 prespecified time points over 72 hours, yielding 900  QT  interval‐plasma concentration time‐matched pairs. Moxidectin had no statistically significant or clinically relevant impact on  QT  interval at any dose level. The primary mixed effects model analysis revealed no treatment‐related impact on the Fridericia‐corrected  QT  interval‐plasma concentration gradient (−0.0077, 90% confidence interval ( CI ) −0.0255 to +0.0101).

Evaluation of the Cardiac Safety of Long‐Acting Endectocide Moxidectin in a Randomized Concentration‐ QT Study